These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26604207)

  • 1. Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells.
    Miao X; Koch G; Straubinger RM; Jusko WJ
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):181-93. PubMed ID: 26604207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
    Lin Q; Qian Z; Jusko WJ; Mager DE; Ma WW; Straubinger RM
    J Pharmacol Exp Ther; 2021 Jun; 377(3):370-384. PubMed ID: 33753538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systems pharmacodynamic model of combined gemcitabine and trabectedin in pancreatic cancer cells. Part I.Çô Effects on signal transduction pathways related to tumor growth.
    Miao X; Shen S; Koch G; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
    J Pharm Sci; 2024 Jan; 113(1):214-227. PubMed ID: 38498417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways.
    Miao X; Koch G; Shen S; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
    J Pharm Sci; 2024 Jan; 113(1):235-245. PubMed ID: 37918792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells.
    Miao X; Koch G; Ait-Oudhia S; Straubinger RM; Jusko WJ
    Front Pharmacol; 2016; 7():421. PubMed ID: 27895579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.
    Belli C; Piemonti L; D'Incalci M; Zucchetti M; Porcu L; Cappio S; Doglioni C; Allavena P; Ceraulo D; Maggiora P; Dugnani E; Cangi MG; Garassini G; Reni M
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):477-84. PubMed ID: 26666646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.
    Zhu X; Straubinger RM; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):477-96. PubMed ID: 26252969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.
    Wang Y; Kuramitsu Y; Kitagawa T; Tokuda K; Baron B; Akada J; Nakamura K
    Target Oncol; 2015 Dec; 10(4):575-81. PubMed ID: 25940934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor effect of interferon-ß with gemcitabine in interferon-α-non-responsive pancreatic cancer cells.
    Tomimaru Y; Eguchi H; Wada H; Tomokuni A; Kobayashi S; Marubashi S; Takeda Y; Tanemura M; Umeshita K; Mori M; Doki Y; Nagano H
    Int J Oncol; 2011 May; 38(5):1237-43. PubMed ID: 21347515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells.
    Hamed SS; Straubinger RM; Jusko WJ
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):553-63. PubMed ID: 23835677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells.
    Molins EAG; Jusko WJ
    AAPS J; 2018 Jun; 20(5):80. PubMed ID: 29951754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.
    Bader Y; Hartmann J; Horvath Z; Saiko P; Grusch M; Madlener S; Maier S; Oehler L; Fritzer-Szekeres M; Heller N; Alken RG; Krupitza G; Szekeres T
    Cancer Lett; 2008 Feb; 259(2):231-9. PubMed ID: 18023527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells.
    Kim R; Yamauchi T; Husain K; Sebti S; Malafa M
    Anticancer Res; 2015 Sep; 35(9):4599-604. PubMed ID: 26254348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
    Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
    Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.
    Yeo D; Huynh N; Beutler JA; Christophi C; Shulkes A; Baldwin GS; Nikfarjam M; He H
    Cancer Lett; 2014 May; 346(2):264-72. PubMed ID: 24491405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.
    Kazim S; Malafa MP; Coppola D; Husain K; Zibadi S; Kashyap T; Crochiere M; Landesman Y; Rashal T; Sullivan DM; Mahipal A
    Mol Cancer Ther; 2015 Jul; 14(7):1570-81. PubMed ID: 25934708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines.
    Whitehouse PA; Cooper AJ; Johnson CD
    Pancreatology; 2003; 3(5):367-73; discussion 373-4. PubMed ID: 14526145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.